Wilkin, Timothy

Publications

Sort by

Co-Author Network

selected publications

High specificity of HPV cell free DNA tests in persons with HIV for the detection of HPV-related cancer. Journal of acquired immune deficiency syndromes (1999). 2023 Academic Article GET IT
CROI 2023: Advances in Antiviral Therapy in HIV and Viral Hepatitis. Topics in antiviral medicine. 2023 Academic Article GET IT
Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2023 Academic Article GET IT
Times cited: 149
A Randomized Clinical Trial of Human Papillomavirus Test-and-Treat as Compared to Cytology-Based Screening for Prevention of Cervical Cancer Among Women With Human Immunodeficiency Virus: AIDS Clinical Trials Group Protocol A5282. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022 Academic Article GET IT
SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8⁺ T-cells. Nature communications. 2022 Academic Article GET IT
Times cited: 5
The Association between Smoking and Anal Human Papillomavirus in the HPV Infection in Men Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2022 Academic Article GET IT
Times cited: 3
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. The New England journal of medicine. 2022 Academic Article GET IT
Times cited: 57
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). AIDS and behavior. 2022 Academic Article GET IT
Sex differences in cytokine profiles during suppressive antiretroviral therapy. AIDS (London, England). 2022 Academic Article GET IT
Times cited: 1
Effects of Sex, Existing Antibodies, and HIV-1-Related and Other Baseline Factors on Antibody Responses to Quadrivalent HPV Vaccine in Persons With HIV. Journal of acquired immune deficiency syndromes (1999). 2022 Academic Article GET IT
Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States. Human vaccines & immunotherapeutics. 2022 Review GET IT
Times cited: 10
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. The Journal of antimicrobial chemotherapy. 2022 Academic Article GET IT
Times cited: 1
Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): A randomized study to prevent anal cancer among persons living with HIV. Contemporary clinical trials. 2022 Academic Article GET IT
Times cited: 8
CROI 2022: advances in antiviral therapy for HIV, COVID-19, and viral hepatitis. Topics in antiviral medicine. 2022 Academic Article GET IT
An Updated Systematic Review of Human Papillomavirus Genotype Distribution by Cervical Disease Grade in Women Living With Human Immunodeficiency Virus Highlights Limited Findings From Latin America. Sexually transmitted diseases. 2021 Academic Article GET IT
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men. Contemporary clinical trials. 2021 Academic Article GET IT
Times cited: 8
Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus: A Randomized, Double-blind, Placebo-controlled Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Academic Article GET IT
Times cited: 9
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. AIDS (London, England). 2021 Academic Article GET IT
Times cited: 8
Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. The lancet. HIV. 2021 Academic Article GET IT
Times cited: 48
Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV. Journal of acquired immune deficiency syndromes (1999). 2021 Academic Article GET IT
Times cited: 2
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. Journal of biomolecular structure & dynamics. 2021 Academic Article GET IT
Times cited: 4
CROI 2021: Advances in Antiretroviral Therapy for HIV and Antiviral Therapy for COVID-19. Topics in antiviral medicine. 2021 Academic Article GET IT
Times cited: 4
Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV. AIDS (London, England). 2020 Academic Article GET IT
Times cited: 10
Sex Differences in CMV Replication and HIV Persistence During Suppressive ART. Open forum infectious diseases. 2020 Academic Article GET IT
Times cited: 8
Another Call for Widespread Human Papillomavirus Vaccination. The Journal of infectious diseases. 2020 Comment GET IT
Prevalence of and Risk Factors for Anal High-grade Squamous Intraepithelial Lesions in Women Living with Human Immunodeficiency Virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Academic Article GET IT
Times cited: 21
Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. The Lancet. Infectious diseases. 2019 Academic Article GET IT
Times cited: 63
Importance of anal cytology and screening for anal dysplasia in individuals living with HIV with an emphasis on women. Cancer cytopathology. 2019 Academic Article GET IT
Times cited: 7
CROI 2019: advances in antiretroviral therapy. Topics in antiviral medicine. 2019 Review GET IT
Times cited: 19
Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men. Vaccine. 2019 Academic Article GET IT
Times cited: 9
A Randomized Clinical Trial of Infrared Coagulation Ablation Versus Active Monitoring of Intra-anal High-grade Dysplasia in Adults With Human Immunodeficiency Virus Infection: An AIDS Malignancy Consortium Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 Academic Article GET IT
Times cited: 29
Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions. Journal of the International AIDS Society. 2019 Academic Article GET IT
Times cited: 10
No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open forum infectious diseases. 2019 Academic Article GET IT
Times cited: 11
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. AIDS (London, England). 2019 Academic Article GET IT
Times cited: 16
Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03). Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2019 Academic Article GET IT
Times cited: 3
No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. PloS one. 2018 Academic Article GET IT
Times cited: 3
Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. Journal of acquired immune deficiency syndromes (1999). 2018 Letter GET IT
Times cited: 9
A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Academic Article GET IT
Times cited: 78
Human papillomavirus-related malignancies in HIV infection: anal and oropharyngeal cancers. Topics in antiviral medicine. 2018 Academic Article GET IT
Times cited: 2
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. The Journal of infectious diseases. 2018 Academic Article GET IT
Times cited: 16
A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men. Papillomavirus research (Amsterdam, Netherlands). 2018 Academic Article GET IT
Times cited: 8
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Academic Article GET IT
Times cited: 80
CROI 2018: Advances in Antiretroviral Therapy. Topics in antiviral medicine. 2018 Academic Article GET IT
Times cited: 4
Initial Development and Content Validation of a Health-Related Symptom Index for Persons either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018 Academic Article GET IT
Times cited: 6
High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298. Sexually transmitted diseases. 2018 Academic Article GET IT
Times cited: 15
Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. AIDS research and human retroviruses. 2018 Academic Article GET IT
Times cited: 10
Cryotherapy Reduces Progression of Cervical Intraepithelial Neoplasia Grade 1 in South African HIV-Infected Women: A Randomized, Controlled Trial. Journal of acquired immune deficiency syndromes (1999). 2017 Academic Article GET IT
Times cited: 7
Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014. Annals of internal medicine. 2017 Academic Article GET IT
Times cited: 101
Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness. Cancer. 2017 Academic Article GET IT
Times cited: 19
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Annals of internal medicine. 2017 Academic Article GET IT
Times cited: 25
Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now. Vaccine. 2017 Academic Article GET IT
Times cited: 18
Prevalence of Anal Human Papillomavirus (HPV) and Performance of Cepheid Xpert and Hybrid Capture 2 (hc2) HPV Assays in South African HIV-Infected Women. American journal of clinical pathology. 2017 Academic Article GET IT
Times cited: 6
Prevalence of Anal HPV and Anal Dysplasia in HIV-Infected Women From Johannesburg, South Africa. Journal of acquired immune deficiency syndromes (1999). 2017 Academic Article GET IT
Times cited: 13
Topical therapies for the treatment of anal high-grade squamous intraepithelial lesions. Seminars in colon & rectal surgery. 2017 Academic Article GET IT
Times cited: 13
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS pathogens. 2017 Academic Article GET IT
Times cited: 122
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults. Journal of acquired immune deficiency syndromes (1999). 2017 Academic Article GET IT
Times cited: 49
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). The Journal of infectious diseases. 2017 Academic Article GET IT
Times cited: 39
CROI 2017: Advances in Antiretroviral Therapy. Topics in antiviral medicine. 2017 Academic Article GET IT
Times cited: 3
Reply to Meijide et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Letter GET IT
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Academic Article GET IT
Times cited: 65
HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. PloS one. 2016 Academic Article GET IT
Times cited: 7
Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy. AIDS (London, England). 2016 Academic Article GET IT
Times cited: 19
Xpert human papillomavirus test is a promising cervical cancer screening test for HIV-seropositive women. Papillomavirus research (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 14
An Insight Into Cervical Cancer Screening and Treatment Capacity in Sub Saharan Africa. Journal of lower genital tract disease. 2016 Academic Article GET IT
Times cited: 17
CROI 2016: Advances in Antiretroviral Therapy. Topics in antiviral medicine. 2016 Review GET IT
Times cited: 6
HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. Annals of internal medicine. 2015 Academic Article GET IT
Times cited: 13
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. AIDS (London, England). 2015 Academic Article GET IT
Times cited: 20
CLINICAL PRACTICE. Primary Care for Men Who Have Sex with Men. The New England journal of medicine. 2015 Review GET IT
Times cited: 16
Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults. AIDS patient care and STDs. 2015 Letter GET IT
Times cited: 6
Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. The lancet. HIV. 2015 Academic Article GET IT
Times cited: 31
CROI 2015: Advances in Antiretroviral Therapy. Topics in antiviral medicine. 2015 Conference Paper GET IT
Times cited: 6
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Annals of internal medicine. 2014 Academic Article GET IT
Times cited: 218
Use of a commercial HIV co-receptor tropism assay in clinical practice. AIDS patient care and STDs. 2014 Letter GET IT
Times cited: 1
Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. The Journal of infectious diseases. 2014 Academic Article GET IT
Times cited: 58
Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201). PloS one. 2014 Academic Article GET IT
Times cited: 1
CROI 2014: Advances in antiretroviral therapy. Topics in antiviral medicine. 2014 Review GET IT
Times cited: 1
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Academic Article GET IT
Times cited: 48
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Academic Article GET IT
Times cited: 117
Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks. American journal of clinical pathology. 2013 Academic Article GET IT
Times cited: 6
Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. AIDS (London, England). 2013 Academic Article GET IT
Times cited: 43
CROI 2013: Advances in antiretroviral therapy. Topics in antiviral medicine. 2013 Review GET IT
Times cited: 8
High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine. HIV clinical trials. 2013 Academic Article GET IT
Times cited: 14
Human papillomavirus vaccines: where do they fit in HIV-infected individuals?. Current HIV/AIDS reports. 2012 Review GET IT
Times cited: 16
Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antiviral therapy. 2012 Academic Article GET IT
Times cited: 20
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. The Journal of infectious diseases. 2012 Academic Article GET IT
Times cited: 66
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clinical trials (London, England). 2012 Academic Article GET IT
Times cited: 89
Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PloS one. 2012 Academic Article GET IT
Times cited: 5
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999). 2012 Academic Article GET IT
Times cited: 95
Advances in antiretroviral therapy. Topics in antiviral medicine. 2012 Review GET IT
Times cited: 12
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV clinical trials. 2012 Academic Article GET IT
Times cited: 7
CCR5 antagonism in HIV infection: current concepts and future opportunities. Annual review of medicine. 2011 Review GET IT
Times cited: 60
Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. The Journal of infectious diseases. 2011 Academic Article GET IT
Times cited: 25
Human papillomavirus vaccination in males: the state of the science. Current infectious disease reports. 2011 Academic Article GET IT
Times cited: 23
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Academic Article GET IT
Times cited: 42
Advances in antiretroviral therapy. Topics in antiviral medicine. 2011 Review GET IT
Times cited: 2
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. The Journal of infectious diseases. 2010 Academic Article GET IT
Times cited: 185
Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial. Therapeutic drug monitoring. 2010 Academic Article GET IT
Times cited: 6
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. Journal of acquired immune deficiency syndromes (1999). 2010 Academic Article GET IT
Times cited: 23
What causes poor CD4-cell recovery in the setting of suppressive ART?. Journal watch. AIDS clinical care. 2010 Article GET IT
Times cited: 1
Advances in antiretroviral therapy. Topics in HIV medicine : a publication of the International AIDS Society, USA. 2010 Review GET IT
Times cited: 4
The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV clinical trials. 2010 Review GET IT
Times cited: 27
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. The Journal of infectious diseases. 2009 Academic Article GET IT
Times cited: 49
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions. Journal of clinical microbiology. 2009 Academic Article GET IT
Times cited: 6
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. The Journal of infectious diseases. 2009 Academic Article GET IT
Times cited: 51
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Academic Article GET IT
Times cited: 17
Antiretroviral rounds. Too many options? 2009 GET IT
Advances in antiretroviral therapy. Topics in HIV medicine : a publication of the International AIDS Society, USA. 2009 Conference Paper GET IT
Times cited: 5
When to start antiretroviral therapy?. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008 Review GET IT
Times cited: 24
CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway. AIDS research and human retroviruses. 2008 Academic Article GET IT
Times cited: 7
Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy. Topics in HIV medicine : a publication of the International AIDS Society, USA. 2008 Conference Paper GET IT
Times cited: 5
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Academic Article GET IT
Times cited: 19
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2007 Academic Article GET IT
Times cited: 431
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. The Journal of infectious diseases. 2007 Academic Article GET IT
Times cited: 230
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet (London, England). 2007 Academic Article GET IT
Times cited: 464
Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. The Journal of infectious diseases. 2007 Academic Article GET IT
Times cited: 58
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS (London, England). 2007 Academic Article GET IT
Times cited: 111
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Academic Article GET IT
Times cited: 167
Advances in antiretroviral therapy. Topics in HIV medicine : a publication of the International AIDS Society, USA. 2007 Conference Paper GET IT
Times cited: 21
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006 Academic Article GET IT
Times cited: 75
Switching antiretroviral therapy: why, when and how. IAPAC monthly. 2006 Academic Article GET IT
Times cited: 2
Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS (London, England). 2006 Academic Article GET IT
Times cited: 34
Advances in antiretroviral therapy. Topics in HIV medicine : a publication of the International AIDS Society, USA. 2006 Conference Paper GET IT
Times cited: 1
Advances in antiretroviral therapy. Topics in HIV medicine : a publication of the International AIDS Society, USA. 2005 Conference Paper GET IT
Times cited: 6
Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy. The Journal of infectious diseases. 2004 Academic Article GET IT
Times cited: 96
Antiretroviral therapy: when and what to start-- an American perspective. Current HIV/AIDS reports. 2004 Review GET IT
Advances in antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA. Topics in HIV medicine : a publication of the International AIDS Society, USA. 2004 Conference Paper GET IT
Times cited: 1
Antiretroviral Therapy: When and What to Start-- An American Perspective. Current infectious disease reports. 2003 Academic Article GET IT
Times cited: 4
Advances in antiretroviral therapy. Topics in HIV medicine : a publication of the International AIDS Society, USA. 2003 Review GET IT
Times cited: 3

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Partnership for advancing cervical cancer prevention in women living with HIV (CASCADE - Research Hub) awarded by National Cancer Institute Principal Investigator 2022 - 2027
Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico awarded by National Cancer Institute Principal Investigator 2019 - 2025

Immunologic control of HIV-1 through combination bNAbs and biologics awarded by Bill & Melinda Gates Foundation Co-Investigator 2019 - 2024
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication awarded by National Institute of Allergy & Infectious Diseases Co-Investigator 2018 - 2023

AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections, ACTG LOC: PF A5357 - Y3 Protocol Vice Chair (1560) awarded by National Institute of Allergy & Infectious Diseases Co-Principal Investigator 2020 - 2027
AMC Domestic Site - Weill Cornell Medicine awarded by National Cancer Institute Co-Principal Investigator 2020 - 2023
Pitavastatin to Reduce Physical Function Impairment and FRailty in HIV (PREPARE) - A5332 substudy A5361s: 1560 B WB699 awarded by National Cancer Institute Co-Principal Investigator 2018 - 2023

Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit awarded by National Institute of Allergy & Infectious Diseases Key Personnel 2020 - 2027

ACTG LOC: PF Chair A5386 - Y3 Protocol co-Chair (1560 G YC266) awarded by National Cancer Institute Principal Investigator Subaward 2020 - 2027
Protocol MCA-1031 Agreement with Rockefeller University awarded by Bill & Melinda Gates Foundation Principal Investigator Subaward 2023 - 2024
ACTG LOC: PF Chair A5418 - Protocol Chair awarded by National Cancer Institute Principal Investigator Subaward 2022 - 2023
AIDS Malignancy Consortium (AMC) - AMC 099 Protocol Chair awarded by National Cancer Institute Principal Investigator Subaward 2020 - 2023
A5332: Prevention of Vascular Events in HIV - REPRIEVE & Substudy A5333s: Pitavastatin on CAD & Inflammatory Biomarkers awarded by National Heart, Lung, & Blood Institute Principal Investigator Subaward 2014 - 2023

more ...

less ...

Background

education and training

M.P.H., Columbia University, School of Public Health 2002
M.D., Ohio State University College of Medicine 1996
B.S., University of Texas 1992

Contact

full name

Timothy Wilkin

primary email

tiw2001@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Timothy Wilkin Assistant Dean for Clinical Research Compliance

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage